hsa-miR-184

ncRNA information

ncRNA name

hsa-miR-184

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

BCL2L1

Cancer information

Cancer name

Osteosarcoma

Cancer site

Bone, Articular Cartilage

Treatment information

Treatment type

Chemotherapy

Drug

Doxorubicin

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

Our data show that miR-184 was up-regulated in OS patients treated with doxorubicin therapy and leads to poor response to drug therapy by targeting BCL2L1.

Tissue resource

human osteosarcoma cell lines U-2

human osteosarcoma cell lines MG-63

Experiment

qRT-PCR,Western blot,Luciferase reporter assay


Institute

the Cell Bank of the Institute of Biochemistry and Cell Biology, China Academy of Sciences

Country

China

Continent

Asia